Source link : https://www.newshealth.biz/health-news/fda-oks-first-il-15-receptor-agonist-for-early-bladder-cancer/
The FDA approved nogapendekin alfa inbakicept (Anktiva) for bacillus Calmette-Guérin (BCG)-unresponsive non-muscle-invasive bladder cancer (NMIBC), the agency announced Monday. A first-in-class interleukin (IL)-15 receptor agonist, the drug is specifically approved in combination with BCG for adults with BCG-unresponsive NMIBC with carcinoma in situ with or without papillary tumors. Approval was supported by data from the […]
Author : News Health
Publish date : 2024-04-23 16:27:57
Copyright for syndicated content belongs to the linked Source.